1 Melenhorst JJ,Levine BL.Innovation and opportunity for chimeric antigen receptor targeted T cells[J].Cytotherapy,2013,15(9):1046-1053.
2 应巧红,钱慧芳.CART技术治疗血液恶性肿瘤研究进展[J].现在医药卫生,2015,31(21):3256-3259.
3 钱磊,崔久嵬.嵌合型抗原受体基因修饰的 T 细胞研究进展[J].中国免疫学杂志,2014,30(6):850-857.
4 张鸿声.嵌合抗原受体 T 细胞肿瘤治疗的前生、今世和将来[J].转化医学杂志,2015,3(3):129-133.
5 Chen R,Song XT,Chen B.CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia[J].Discov Med,2015,20(110):185-190.
6 常征,陈学武,王丽,等.嵌合抗原受体T细胞治疗恶性肿瘤的研究进展[J].药学研究,2015,34(9):534-536.
7 Tasian SK,Gardner RA.CD19-redirected chimeric antigen receptor-modified T cells:a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia(ALL)[J].Ther Adv Hematol,2015,6(5):228-241.
8 Maude SL,Teachey DT,Porter DL,et al.CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J].Blood,2015,125(26):4017-4023.
9 Singh H,Figliola MJ,Dawson MJ,et al.Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cell[J].PLoS One,2013,8(5):e64138.
10 Leen AM,Rooney CM,Foster AE.Improving T cell therapy for cancer[J].Annu Rev Immunol,2007,25:243-265.
11 赵嫄,胡婉丽,张连生.嵌合抗原受体疗法在血液肿瘤免疫治疗中的研究进展与应用前景[J].中华临床医师杂志,2014,8(6):1158-1161.
12 Stephen JS,Jakub S,Sunita DN,et al.Sustained remissions following chimeric antigen receptor modified T cells directed against CD19(CTL019)in patients with relapsed or refractory CD19+ lymphomas[R].Orlando:Orange County Convention Center,2015.
13 Topp MS,Kufer P,Gokbuget N,et al.Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival[J].J Clin Oncol,2011,29(18):2493-2498.
14 Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385(9967):517-528.
15 Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509-1518.
16 Gardner RA,Jensen MC.CD19CAR T cells:from humble beginnings to cancer immunotherapy′s poster child[J].Cancer J,2014,20(2):107-111.
17 Kebriaei P,Huls H,Singh H,et al.Adoptive therapy using sleeping beauty gene transfer system andartificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor[R].San Francisco:Moscone West Convention Center,2014.
18 Lee DW,Gardner R,Porter DL,et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124(2):188-195.
19 Maude SL,Barrett D,Teachey DT,et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J].Cancer,2014,20(2):119-122.
20 Maude SL,Frey N,Shaw PA,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371(16):1507-1517.
21 Marco R,David MB,Saad SK,et al.Combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells for the treatment and prevention of antigen-loss relapses occurring CD19 targeted immunotherapies[R].Orlando:Orange County Convention Center,2015.
22 Mardiros A,Forman SJ,Budde LE,et al.T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia[J].Curr Opin Hematol,2015,22(6):484-488.
23 Pinz K,Liu H,Golightly M,et al.Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor(CAR)-engineered T cells[J].Leukemia,2016,30(3):701-707.
24 Topp M,Gokbuget N,Zugmaier G,et al.Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia[J].J Clin Oncol,2014,32(36):4134-4140. |
